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1. Introduction
Japanese encephalitis virus (JEV) is a flavivirus, which is an emerging threat globally, major‐
ly being southern and Southeast Asia and Australia. Even though most JEV infections are
asymptomatic, it is estimated that only 0.3% leads to disease causing and results in over
35,000 cases including 10,000 deaths annually worldwide, and remaining cases which some‐
how escape death produce permanent sequelae, proving to be as a persistent threat (Singh et
al., 2012). The human infections caused by encephalitic flaviviruses are more often asympto‐
matic or they cause mild febrile illness but sometimes this low percentage of mild infection
turns into a dangerous and life-threatening encephalitis. The conditions which support viral
survival are concerned to both viral and host factors that allow virus entry from the blood
into the central nervous system (CNS). Host factors play important role in disease suscepti‐
bility. Japanese encephalitis, caused by JEV which belongs to arthropod-borne virus family
and transmitted through Culex mosquito, is centrally a pediatric disease which causes acute
infection and inflammation of the brain. Historically, in 1817 JE was first identified in Japan,
but the causative agent (JEV) was later isolated from a fetal human case in 1934 (Erlanger et
al., 2009). First report of JE in India was in 1955, and since then this deadly virus has en‐
gulfed thousands of lives and has shaken several economies. The total numbers of cases re‐
ported annually are about 35,000-50,000 (Zheng et al., 2012). Out of these reported cases
~30-50 % patients suffer from neurological sequelae and ~20-40 % cases turn to be fatal (Nett
et al., 2009). The actual counts are still higher than reported due to lack of reach of technolo‐
gy and surveillance towards extreme rural areas, which contain more vulnerable and needy
population. The natural cycle of JEV consists of pig-mosquito-pig or bird-mosquito-bird
(van den Hurk et al., 2009) circulation of virus. When an infected mosquito bites a healthy
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individual, it may lead to febrile illness or a severe meningoencephalomyelities illness
which is life taking. The incidence of the disease intensifies in rainy season as the environ‐
ment supports the viral growth because of temperature, moistness and dampness which are
plus factors letting the virus to bloom and flourish (Saxena et al., 2008) (Fig.1). Today the
need is to fight against this reemerging virus by the aid of high level of immunization and
therapeutic and preventive measures to slow down the spread of the disease amongst hu‐
man population.
Figure 1. Displaying the contributing factors, which are responsible for the emergence and reemergence of JEV.
2. Genome of the virus
Japanese encephalitis virus belongs to the Flaviviridae family, it is an RNA virus measuring ~
40-50 nm in diameter and structurally it is a spheroid having cubical symmetry. It is an en‐
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veloped virus having single stranded RNA as a genome which is infectious. The genome is
of ~11kb with positive sense and a 5’ cap but it lacks a 3’ poly tail (Vashist et al., 2011). It
contains nucleocapsid which is surrounded by a lipid envelope. The genomic RNA contains
a single open reading frame (ORF) and codes for a polyprotein of ~3400 amino acids. This
polyprotein is cleaved by viral and host proteases into 10 proteins. Structural genes are three
in number and are involved in antigenicity since they are expressed on the virus coded by
capsid protein and involved in capsid formation: core (C), pre membrane (prM) and enve‐
lope (E). Among all three the E gene is the most important and is the most studied one.
There are seven non structural genes: NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5 (Fig.2) and
these are involved in virus replication (Saxena et al., 2011). A novel mutation in domain II of
the envelop gene of JEV circulating in North India has been reported (Pujhari et al., 2011).
The high rate of mutation in JEV is due to RNA dependent RNA polymerase (RdRp) coded
by NS5 (Neyts et al., 1999). JEV replicates exclusively in the cytoplasm of infected cells, in a
perinuclear location, and matures on intracellular membranes.
Figure 2. The genome of Japanese Encephalitis Virus, constituting the 3 Structural genes: C, prM, E and 7 Non-struc‐
tural genes: NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5.
Japanese encephalitis (JE), caused by Japanese encephalitis virus (JEV), is the most impor‐
tant form of viral encephalitis in Asia. The epidemiology of JE has changed in the past 50
years and the area affected by JEV has expanded to India, China, Southeast Asia and West‐
ern Pacific regions. About 50, 000 cases and 10 000 deaths are reported in JEV-endemic areas
among a population of 3 billion people. However, the true number is unknown, because
most areas where JEV occurs lack diagnostic facilities. Most JEV infections are subclinical.
JEV is a member of the JEV serological complex, which causes significant morbidity and
mortality. Pigs are the most important biological amplifiers and reservoirs. Generally direct
person to person spread of JEV does not or rarely occurs until it is through intrauterine
transmission (Guy et al., 2010). Blood and organ transplantation also serve as a mode of
transmission. JEV infection transmits from mother to foetus through vertical mode of trans‐
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mission (Mathur et al., 1982). Symptomatic infections are usually present in the form of non-
specific febrile illness, including diarrhoea and rigors followed by headache, vomiting and
reduced levels of consciousness and aseptic meningitis or encephalitis. The incubation peri‐
od after JEV exposure varies from 6 to 16 days (Saxena et al., 2009). One in 200/800 infected
people develop clinical signs like high fever and nausea. A quarter of patients with symp‐
toms die; a third of survivors suffer brain damage.
3. Epidemiology
Encephalitis outbreaks have been recorded since early 19th century from countries like
Southeast Asia including Japan, Vietnam, Cambodia, Myanmar, India, Nepal, Malaysia,
China, Korea, Taiwan, Thailand and reached to the West including Pakistan and the north‐
east and southwest of India, also the East (New Guinea), the South (Northern Australia Ar‐
chipelago) and it is estimated theoretically to spread further West (Afghanistan). Between
1978 and 1992, 24 imported cases were reported in above regions due to high transmission.
Since the 1990s, the JE is variedly transmitting in humans and is reaching new extended re‐
gions encompassing new geographic limits. History tells that a woman in France suffered
from JE after she reached Thailand, in 1938. Also JE epidemic was reported in restricted sea‐
coast of the ‘USSR’ in 1939. Also in 1946 major outbreaks of JE were recorded in Korea, both
in civil in 1949 and in American military personnel in 1950.
Sequencing analysis divides JEV into five genotypes (GI–V) rising from ancestor viruses
from Indonesia–Malaysia region. These ancestors have evolved into five genotypes; GI, GII,
GIII, GIV and GV, out of them GIV and GV are the most divergent. They always remained
confined to their origin region of Indonesia–Malaysia. However GI, GII and GIII are the
most recent genotypes which have spread across Asia. All phylogenetic characterization and
studies done on a large scale highlights GIII as a predominant genotype of JEV in Japan and
Korea since 1935 (Schuh et al., 2009). GI was been isolated in Cambodia and then in China in
1979 and GIII was isolated before the 1970s and then in Vietnam and Japan during 1986 and
1990. Later even GI was reported there in 1995 and 2002 proving that all the strains isolated
before 1991 were GIII, and after 1994 were GI. The natural cycle of JEV consists of pig-mos‐
quito-pig or bird-mosquito-bird cycles. GIII was the only widely distributed genotype found
in India until till when GI JEV strains were detected and isolated from 66 acute encephalitis
syndrome (AES) patients along with GIII strains (Fulmali et al., 2011). This detection indi‐
cates their co-circulation and association with humans. In the mid 1990’s genetic shift (Nabe‐
shima et al., 2009) had occurred in Japan, Korea and Vietnam that lead to disappearance of
GIII and then progressively GI supplanted it (Zhang et al., 2011). In India exact mode of in‐
troduction of GI is not clear, but it is possible that it may have been introduced through mi‐
gratory birds (Huang et al., 2010).
JEV is basically transmitted by Culex spp mosquitoes. JEV is distributed in temperate and
tropical  areas  of  eastern  and  southern  Asia.  Its  range  has  extended  from  eastern  Asia
(China, Japan, Korea, maritime Siberia, Taiwan, the Philippines, and Vietnam), to South‐
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east  Asia  and  northern  Australasia  (Cambodia,  Indonesia,  Laos,  Malaysia,  Papua  New
Guinea,  Thailand,  and the  Torres  Strait  islands  of  northern  Australia),  and  to  southern
Asia  (Bangladesh,  Bhutan,  India,  Myanmar,  Nepal,  and  Sri  Lanka)  (Fig.  3).  Evidences
have also been seen for Pakistan. JE is largely a disease of rural areas, especially associat‐
ed with irrigated rice agriculture. During endemics, no seasonal pattern exists and spora‐
dic  cases  of  encephalitis  occur  throughout  the  year,  most  often  in  infants  and  young
children.  There is  a  peak in  vector  density  and virus  activity  during October-December
in endemic zones. However, epidemic activity in temperate and subtropical areas occurs
most commonly in summer and early autumn (van den et al., 2009).
Figure 3. Epidemiology of JE globally. The areas highlighted in black display the regions under the attack of JEV infec‐
tions and are high infection prone areas.
From past 75 years the major focus of JE coverage was on China and Southeast Asia, but
now it  has  extended its  horizons  to  westward towards  India  and Pakistan,  northern to
eastern Russia, eastward towards Philippines and southward to Australia. Occurrence of
JE  is  more  closely  related  to  temperature  and  humidity  in  the  atmosphere  (Misra  and
Kalita,  2010).  JEV is  also  engulfing  new geographical  regions  which  are  shown by  JEV
sequencing analysis and results exhibit  that JEV is expanding alarmingly to the new re‐
gions of  Papua New Guinea and Australia.  GI  strains  are  often isolated from Northern
Thailand, Cambodia,  Korea,  China,  Japan, Vietnam, Taiwan and Australia between 1967
and  the  present.  GII  are  isolated  from  Southern  Thailand,  Malaysia,  Indonesia,  Papua
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New Guinea  and Northern  Australia.  GIII  are  isolated from temperate  regions  of  Asia.
GIV are isolated in Indonesia and GV is isolated in Singapore. Sequence analyses of viral
genes  are  further  showing  that  a  “genotype  shift”  from  III  to  I  has  occurred  in  Japan
since early 1990s,  reasons for  which remains unclear  (Shimojima et  al.,  2011).  Consider‐
ing India, rapid spread of Japanese encephalitis (JE) towards the newer areas of northern
states of India is also reported (Saxena et al., 2006, 2009).
4. JEV: Infectious agents
The genomic RNA of JEV is ~11 kb in length encoding three structural proteins and sev‐
en non-structural proteins. The RNA genome of the virus is infectious which can spread
the  horizon  of  disease.  The  virus  genome  contains  C  proteins  complexed  with  the  ge‐
nomic RNA present in a nucleocapsid, and this whole complex is surrounded by envel‐
oped lipid bilayer containing E and prM/M proteins, which is derived from the infected
host cells.  The prM proteins present in the immature particles,  cleave to mature into M
proteins. The E protein is the major infectious part which covers the entire surface of the
mature virion, and it  is the antigen majorly recognized by virus neutralizing antibodies.
Further, subviral particles (SVPs), containing prM/M and E proteins enclosed in lipid lay‐
ers but not surrounded by nucleocapsid, are secreted from flavivirus infected cells, prov‐
ing these SVPs to be as excellent immunogens. Along with infective E protein, even NS1
protein is also considered as quite infective which may cause lethal effects to hosts when
produced and expressed in large quantities. If antiNS1 immunity steps are taken and cy‐
tolytic  antibodies  against  NS1 are  administered,  it  would contribute  in  the reduction of
the release of progeny viruses from infected cells. Hence a drug with a mixture of antiE
and antiNS1 immunity would definitely pose as a potent fighter against flavivirus infec‐
tion (Ishikawa et al., 2011).
5. Transmission of disease
JE virus undergoes zoonotic cycles which involve mosquitoes and several vertebrate species
as hosts and human beings as dead end hosts. Culex tritaeniorhyncus and Culex gelidus are
reported as principal vectors. These vectors breed in rice fields, irrigation canals and water
pools filled with stagnant water and in standing puddles, open sewers, fish ponds etc. These
infected mosquitoes (~3%) bite domestic animals and birds, but sometimes they may bite a
healthy host (human), which are accidental hosts, facilitating the transmission of the virus to
man. Pigs and birds serve as reservoirs and amplifying hosts. Man is an incidental host of
the JEV (Fig. 4). In humans, after a bite of infected mosquito, initial viral replication occurs
in local and regional lymph nodes. Viral invasion of the central nervous system occurs prob‐
ably via blood causing infection and subsequent illness.
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Figure 4. Life cycle of JEV crossing through important vectors and intermediate hosts and finally to dead end reser‐
voirs human hosts.
6. Pathogenesis and pathology
The majority of human infections with encephalitic flaviviruses are asymptomatic or give
rise to only a mild febrile illness. However, in a small percentage of infected individuals the
mild infection turns into life-threatening encephalitis. Thus, a key question in the pathogen‐
esis of encephalitic flaviviral disease concerns the conditions that allow virus entry from the
blood into the central nervous system (CNS). Hypertension, diabetes mellitus, and coinfec‐
tion with other virus may further deteriorate the infection and can worsen the condition of
infected persons by increasing neurological complications which may happen due to facili‐
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tation of virus across the blood–brain barrier (Singh et al., 2009). Histological examination
shows that virus can affect neurons present in thalamus and brain. Viral antigen is later gets
cleared from there due to the induction of adaptive immune. A strong virus-specific anti‐
body response, in CNS may act for recovery from encephalitic infection. Clinical infections
with the mosquito-borne encephalitic flaviviruses in humans mostly occur in the absence of
detectable viremia consistent with the notion that humans are dead-end hosts in the natural
transmission cycle (Müllbacher et al., 2003).
Japanese encephalitis (JE) is now the foremost cause of viral CNS infection. JEV pathogene‐
sis is still unclear (Yang et al., 2011). Since the variation exists in neuro-virulence and periph‐
eral pathogenicity among JE virus strains. After the infected mosquito bite, the virus enters
into the reticulo-endothelial system and invades the central nervous system after the transi‐
ent period of viremia. It distributes itself in hypothalamus, hippocampus, substantia nigra
and medulla oblongata regions of brain via vascular endothelial cells by the mechanism of
endocytosis which involves cholesterol and clathrin mediated pathways, referred to as lipid
rafts acting as portals for virus entry (Das et al., 2010). The virus replicates in neurons and
matures in the neuronal secretary system. Nearly 33% of JE infected patients die due to neu‐
rocysticercosis (NCC), suggesting that it may somehow predispose to JE (Desai et al., 1997).
During acute stages congestion, edema, hemorrhagic symptoms are found in brain. Patho‐
logical changes in the neural tissues have also been reported in lymphoid organs and im‐
mune cells such as spleen and kupffer cells respectively.
7. Immune response
The pathogenesis of the neurotropic flaviviruses like JEV, involves both virus-mediated
damage and the host immune responses. After the mosquito bite, when the virus is inoculat‐
ed in the host, it replicates in skin dendritic cells, and then is transported to lymph nodes,
from where it spreads to peripheral organs, enhancing the viremia. Entry into CNS is an im‐
portant event which aids viral encephalitis [9]. Roles of both the innate and adaptive im‐
mune responses in controlling flaviviral infection are important. IgM and IgG are involved
in preventing viral dissemination to the CNS, however CD8+ T cells are important for recov‐
ery and immunopathological phases of viral infection.
Infection with flavivirus triggers the host’s innate immunity, resulting in signalling path‐
ways and production of interferons (IFN) which are secretory cytokines produced as a re‐
sponse against viral infection. When these IFN bind to the cell-surface receptors, Jak–Stat
signaling pathway is activated which in turn induces the transcription of interferon-stimu‐
lated genes (ISGs), and the resulting products have potent antiviral, antitumor, and immu‐
nomodulatory effects. To win against the IFN defence system, viruses encode viral proteins
which are potent enough to block IFN signaling, via various mechanisms (Sen 2001, Weber
et al., 2004) like blocking IFN action by preventing Tyk-2 phosphorylation by the production
of NS5 protein of JEV (Lin et al., 2004; Lin et al., 2006;Liang et al., 2009).
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8. Host immune responses
The virus enters the neuro-parenchyma by crossing capillary walls in the brain and distrib‐
utes itself in various parts of brain. Initially JE virus is partially destroyed at its site of entry
and the remaining virus is disseminated by local and systemic extra neural replication lead‐
ing to viremia. After primary infection with JEV, presence of IgM antibodies and T-lympho‐
cytes are seen until 2 weeks approximately. But antibodies alone are neither capable of
terminating the viremia nor preventing the subsequent infection. Pregnancy is known to
cause immunosuppression and persistent maternal infection or pregnancy induced reactiva‐
tion of the virus which causes foetal infection. Isolation of JEV from human placenta and
foetuses has been reported. JEV can establish latency within different organs despite the
presence of antiviral antibodies. A significant decrease in serum iron levels, a frequent fea‐
ture of microbial invasion is observed during JE infection. An early influx of macrophages
followed by neutrophils at the site of injury in different organs of humans and mice has
been reported, which is correlated with the production of a neutrophil chemotactic macro‐
phage derived factor MDF, with development of hypoglycemia. This chemotactic protein
(MDF) has been shown to play a protective role in the host defense against JEV, through
production of reactive oxygen intermediates in neutrophils and reactive nitrogen oxide spe‐
cies degrading the virus protein and RNA (Tiwari et al., 2012).
The earliest  host response to viral  infection is  the induction of IFN. Type I  IFNs, IFN-α
and β are produced by leukocytes and fibroblasts,  respectively,  in response to infection
and activate the transcription of a host of IFN inducible genes that leads to the induction
of  antiviral  pathways.  IFN-α  has  important  immunoregulatory  functions  including  the
activation of monocytes,  enhancement of chemokine expression and MHC class I  and II
induction. Most of the antiviral activity of IFN-α is mediated by NO radicals synthesized
by monocytic  phagocytes,  mortality  in  JEV-infected mice increased when the activity  of
NO synthase was inhibited (Saxena et  al.,  2000,  2001) as NO blocks mechanism of viral
RNA  and  protein  synthesis  (Müllbacher  et  al.,  2003).  Also  natural  killer  (NK)  cells  are
important  part  of  the  innate  immune  response  which  is  activated  at  the  viral  invasion
which helps in early defence as NK cells synthesize and regulate cytokines, necessary for
adaptive immune response.
9. Adaptive immune response
The  importance  of  humoral  response  in  recovery  from encephalitis  is  demonstrated  by
several  studies  showing that  administration of  antibody during early  infection can pro‐
tect against JE. Studies of the entry process of JEV using electron and confocal microsco‐
py  techniques  showed  that  neutralizing  mAb  strongly  inhibits  JEV-induced  fusion  and
internalization into  cells,  but  not  binding of  virus  to  cells.  T  cells  are  of  crucial  impor‐
tance for the recovery from most virus infections and individuals deficient in T cells are
unable to control virus infections. T cells are necessary for recovery and protection after
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JEV infection and also their  depletion affects the humoral and cellular,  immune defence
against flavivirus infections (Müllbacher et al., 2003).
10. RNAi effect on JE
Inhibitory effect of RNAi on JEV replication has been thoroughly studied in vitro and in vivo
(Murakami ET AL., 2005). It is also reported that defective interfering (DI) RNA aids in the
persistence of JEV (Yoon et al., 2006). Effectiveness of using siRNA expression based vectors
targeting the JEV NS5 gene to inhibit JEV replication, viral protein expression, and RNA lev‐
els of JEV E-protein is hot topic of research nowadays. Several studies demonstrate that
shRNAs targeting the NS5 gene could specifically and efficiently inhibit JEV replication.
Many researchers have shown that siRNA/shRNAs targeting the RdRP coding gene could
efficiently inhibit viral replication; the inhibition of viral replication triggered by siRNA/
shRNA targeting of the RdRP gene are reported to be more efficient compared to other
genes from the genome (Neyts et al., 1999). Therefore, the NS5 gene which is highly con‐
served among different strains is often employed as an RNAi target for different studies.
shRNAs targeting NS5 gene in the JEV genome are shown to be capable of interfering with
JEV replication with very high specificity and efficiency. Hence shRNAs could be used as a
potential tool against JEV replication in vitro. More research investigating RNAi methodolo‐
gies to prevent infection or reduce viremia is necessary which may lead to the development
of antiviral compounds that are efficacious and inexpensive against Japanese encephalitis
infections (Qi et al., 2008).
11. JAK-STAT pathway for JE
IFN-α  and  IFN-β,  play  important  role  in  recovery  from  flaviviral  infections.  However,
they  fail  sometimes  due  to  ability  of  JEV to  inhibit  the  JAK-STAT (Janus  kinase  signal
transducer  and  activator  of  transcription)  pathway  (Lin  et  al.,  2006).  Studies  of  DEN-2
antagonism of  STAT1 phosphorylation  have  revealed  NS4B as  the  primary  and impor‐
tant antagonist. Still the exact mechanism of IFN antagonism is under study. The specific
receptor complex for each IFN-α and IFN-β is composed of two major subunits and sev‐
eral  JAK tyrosine  kinases  constitutively  associated  with  the  receptor.  Jak1  and Jak2  are
required for  IFN-α/β  signaling.  Following binding of  the  receptor  subunits  by  IFN,  the
JAKs  trans-phosphorylate  each  other  and  then  phosphorylate  critical  tyrosine  residues
within  the  intracellular  domains  of  the  receptor  subunits  (Lin  et  al.,  2004).  These  phos‐
phorylated residues serve as recruitment sites for STAT proteins, which bind the activat‐
ed  receptor  and  are  in  turn  phosphorylated  by  the  JAKs.  The  phosphorylated  STAT
proteins then form homodimers, or heterodimers, with other STAT proteins and translo‐
cate  to  the  nucleus,  where  they  bind  specific  DNA  sequences  within  the  promoter  re‐
gions  of  IFN-stimulated  genes  (ISGs)  (Fig.  5).  ISG expression  induces  an  antiviral  state
within the cell, can modulate cell proliferation and cell death, and modulates immune re‐
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sponses via its roles in activation and maturation of antigen-presenting cells.  The ability
of  the  individual  non-structural  proteins  to  antagonize  JAK-STAT  signaling  has  been
studied and results indicated that NS5 blocked STAT1 phosphorylation in response to ei‐
ther IFN-α or IFN-β which highlights the function of NS5 to have a critical role in virus
pathogenesis (Best et al., 2005).
Figure 5. Displaying the JAK STAT Pathway. JAK STAT signaling pathway is important for transduction of information
between cells carrying information for cellular differentiation and homeostasis. Cytokines and their receptors are the
major activator of JAK/STAT pathway. IFN are antiviral cytokines produced by cells as soon as the onset of viral infec‐
tion. IFN-α and IFN-β bind to different receptors and, play important role in recovery from flaviviral infections. Howev‐
er, they fail sometimes due to ability of JEV to inhibit the JAK-STAT pathway.
12. Diagnosis
Serology is an important tool for the diagnosis of JE since the virus is difficult to isolate
from clinical samples. The hemagglutination inhibition assay also is used but it has prac‐
tical  limitations  as  it  requires  paired  serum  samples  from  the  acute  and  convalescent
phases.  The  IgM  antibody  capture  ELISA  for  CSF  and  serum  samples  is  currently  the
standard test for diagnosis of JE but still has the drawback of not being able to diagnose
about  the  infection in  early  stage.  Molecular  methods using reverse-transcriptase  (RT)  -
PCR techniques have proved to be highly effective for diagnosing infection by RNA vi‐
ruses.  JE  viral  genome  sequences  have  been  detected  by  RT-PCR  in  CSF  from  acute
encephalitis  cases  from several  places  around the globes.  The conventional  RT-PCR has
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shown good specificity in the diagnosis of JEV in both blood and CSF samples but it has
poor  sensitivity  as  the  virus  is  often cleared from the peripheral  circulation/CSF by the
time the test  is  performed. With the advent of  monoclonal  antibodies as potential  diag‐
nostic  tool  (Chávez et  al.,  2010),  the rapid detection of  JE antigen in cerebrospinal  fluid
has become possible. The different diagnostic tests have been given in Table 2. However,
the  most  rapid  and  potential  diagnostic  tool  for  JE  diagnosis  have  been  shown  to  be
MAC-ELISA (Robinson et  al.,  2010)  and indirect  fluorescent  antibody.  MRI  of  the  brain
can also be used in diagnosis. MRI changes can be co-related (Misra et al., 2011) with the
type of encephalitis and duration of illness.
13. Vaccines: Immunization against JE
Immunization against JE is cost effective strategy for control and prevention of JE. It has
been reported globally that there is a decrease in incidence rates of JE in endemic areas
which are administered with high immunization. The 3 most important types of JE vac‐
cines, administered in current era are: the mouse brain derived, purified, inactivated vac‐
cine  based  on  either  the  Nakayama  or  Beijing  strains  of  the  JE  virus;  the  cell  culture
derived inactivated  JE  vaccine  based  on  the  viral  Beijing  P3  strain  and the  cell  culture
derived live attenuated JE vaccine based on the SA 14‐14‐2 strain of the JE virus. In JEV
infection,  the immunity against  prM, E and NS1 proteins  is  more effective than that  of
other  viral  proteins  in  host  defense.  (Gao  et  al.,  2010).  Currently  available  vaccines
against  JE  include  chemically  inactivated  vaccines  (INV)  and  a  live  attenuated  vaccine
(LAV). Although a mouse brain derived INV produced by BIKEN had been the only in‐
ternationally approved vaccine and has been used worldwide since the 1960s. But it had
a drawback as there were reports of severe adverse events including acute disseminated
encephalomyelitis (ADEM) in people vaccinated with it.  In early 2009, Vero cell  derived
INVs produced by Intercell  (Austria)  and BIKEN (Japan)  were licensed.  Although these
INVs are useful in developed markets, INVs are not ideally suited for nationwide vacci‐
nation  programs for  many endemic  countries,  since  INVs  require  multiple  doses  to  in‐
duce long lasting immunity.  LAVs are thus a useful alternative and have been used for
decades  in  China,  and  other  Asian  countries,  but  their  substrate  and  the  production
methods  have  still  not  been approved in  other  markets,  which  serve  as  a  drawback to
this vaccine. (Ishikawa et al.,  2011).  Live-attenuated virus vaccines (LAVs) and inactivat‐
ed virus vaccines (INVs) serve against flaviviral disease, they are potent and economical
but do not suit immunocompromised patients. INVs are safer, but are more expensive to
produce  and  less  potent.  Hence  there  is  an  immense  need  of  devicing  new  and  im‐
proved products.
Type I IFNs are critical for controlling pathogenic virus infections and can enhance immune
responses. Hence their impact on the effectiveness of live-attenuated vaccines involves a bal‐
ance between limiting viral antigen expression and enhancing the development of adaptive
immune responses. The influence of type I IFNs on these parameters has been examined fol‐
lowing immunization with RepliVAX WN, a single-cycle flavivirus vaccine (SCFV). Repli‐
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VAX WN-immunized mice produced IFN-α and displayed increased IFN-stimulated gene
transcription (Winkelmann et al., 2012). Multiple vaccines exist to control Japanese encepha‐
litis (JE), but all suffer from problems but this new flavivirus vaccine, a pseudoinfectious vi‐
rus (RepliVAX WN) that expresses the JE virus (JEV) prM and E proteins prevents flaviviral
disease. Engineered second-generation RepliVAX (RepliVAX JE.2) elicited neutralizing anti‐
bodies in experimental mice and provided 100% protection from a lethal challenge with JEV
(Ishikawa et al., 2008).
Although a licensed vaccine has been available to prevent JE for over 40 years, approxi‐
mately  20,000  cases  are  reported  annually  with  6000  resulting  in  death.  Unfortunately,
due to gaps in surveillance, the incidence of JE is also likely to be much higher than re‐
ported. A number of different vaccines are available to prevent JE and these have dem‐
onstrated  an  excellent  record  of  efficacy  throughout  their  history.  The  vaccine  that  has
been in use the longest  is  the INV prepared from JEV infected mouse brains.  This  vac‐
cine has been used extensively in East Asia since the 1960s to control JE,  and is widely
used throughout the world to immunize travellers who visit endemic areas, its protective
efficacy is reported to be 80–90% in JEV endemic regions. But still it has a drawback that
the product requires a three dose vaccination schedule in order to induce protective im‐
munity  and  this,  along  with  the  recommendation  of  boosters  every  2–3  years  which
poses  as  quite  expensive  for  nominal  patients  from  low  income  group  countries  and
time-consuming  too.  Furthermore  they  are  also  reported  for  causing  allergic  reactions
and more dangerous side effects  like  complications  including severe  neurological  disor‐
ders such as acute disseminated encephalomyelitis,  etc  in people being administered by
the vaccine (Widman et al., 2008).
Through vaccination in the last five year, JE has been effectively controlled and eliminated
in China, Japan, Taiwan, and Korea (Chung et al., 2007; Takahashi et al., 2000; Jelinek et al.,
2009). Second generation recombinant vaccines are also being developed, where genes en‐
coding prM and E proteins are packed into vectors. DNA based JEV vaccines which may be
very efficient against the virus are under clinical trials. DNAzymes cleave the RNA se‐
quence of the 3’-NCR of JEV genome in vitro, on intra-cerebral administration in JE infected
mice almost completely (Appaiahgari et al., 2007) and inhibit virus replication in the brain.
Use of neutralizing bodies for vaccine designing may also serve the process.
14. Treatment, prevention and control
There is no specific treatment or anti-viral agent for JEV infection, it is proving to be a per‐
sistent threat. Monoclonal antibodies (Yamanaka et al., 2010), corticosteroids, interferonα-2a
or ribavirin were not that effective in clinical outcome. The effect of rosamarinic acid (RA)
has been shown as an effective anti-viral agent that reduces JE viral load along with proin‐
flammatory cytokines in experimental animal. Neutrophils have been also shown to have
degradative effect on JEV. Usage of anti-sense molecules (vivo-morpholino) directed against
the viral genome, in combating the virus through inhibiting viral replication has been dem‐
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onstrated (Nazmi et al., 2010). Mycophenolic acid (Sebastian et al., 2011) inhibits JE virus by
inhibiting its replication.
Prevention methods are very important for minimizing JE infection (Saxena et al., 2008).
Childhood immunization is done by using inactivated mouse brain-derived vaccine which
is based on either the Nakayama or Beijing strains of the JE virus, the cell culture derived,
inactivated JE vaccine based on the Beijing P-3 strain ; and the cell cultures derived, live –
attenuated vaccine based on the SA 14-14-2 strain (Halstead et al., 2011) of the JE virus. Re‐
combinant poxvirus vectors expressing the E and NS1 proteins of the JEV boosting a good
immune response in mice models can be used as a vaccine. The prevention of vector –man
contact is very good preventive method this can be done by eliminating potential mosquito
breeding areas, environmental sanitation, waste water management by treating the water
with larvicide either by Gambusa (larva-eating fish), drying and wetting of rice fields, fre‐
quent vaccination should be implemented, and as well as personal protective measures. Re‐
ports have shown that induction of nitric oxide synthase plays a protective role against JEV
(Saxena et al., 2001). Diethyldithiocarbamate has been also experimentally shown to inhibit
JEV infection. Future predictions of the disease and drug designing can be enhanced by
computer aided design databases, which can design in silico the most efficient drugs which
can be tested experimentally and then can be clinically tried. For the development of appro‐
priate and effective therapy there is an immediate need to understand host factors role in
JEV –induced neuropathogenesis (Gupta et al., 2011). Effective anti-viral drugs have yet to
be found. Medicines are given mainly to relieve symptoms. Vaccination for people at risk,
eliminate mosquito breeding grounds, improve drainage, maintain clean piggeries, use in‐
sect repellent and mosquito nets are some of the preventive measures which should be com‐
monly undertaken.
The strategy for prevention and control of JE should include major components such as
awareness among general public on the prevention and control of the disease, vector control
and immunization. Environmental control is also one important factor as it has been studied
that there is a positive impact of urbanization and economic development in the reduction
of JE transmission, as clean and sanitized economies will not support environment necessa‐
ry for mosquito breeding. Land areas under cultivation with impact of agrochemicals may
work for reduction of vector density. Along with good environmental strategies vector con‐
trol is also an important aspect. Maintenance of low vector densities is the need of hour.
Spraying, larviciding and aerial application are the method used for reduction of vector den‐
sities. However, alternatives to aerial application like spraying/fogging/Ultra Low Volume
(ULV) application are also under consideration. Along with this long term i.e. non‐chemical
vector control such as water management is also helpful. Use of agrochemicals to control
pests may have had indirect effect on vector control. Also, use of larvivorous fish may also
be applicable in permanent water bodies. Personal protection is very important as vectors
can feed on humans in outdoors, hence over vegetation and shaded humid places should be
bit ignored. Minimizing outdoor activity for reducing the exposure time to mosquitoes and
wearing long sleeved clothes are some habits needed to be undertaken consideration along
with public information and awareness.
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15. Conclusion and future implications
Viral encephalitis has proved to be a huge disaster globally, which has engulfed several
lives and has shattered various economies. It has been a hot topic amongst the researchers
today globally and various ways necessary to combat against the virus are on the way. In‐
tense research for the knowabouts of the virus is carried in several countries, devising strat‐
egies to fight with the virus. As a result of severe efforts, JE has been virtually eliminated in
most of the countries after the immunization with inactivated mouse brain-derived vaccine,
during last four decades. Because of absence of treatment strategies personal protection is
the only apt way to reduce disease incidence. Mosquito control is the sole available preven‐
tive measure for JEV transmission. Research on JEV needs to be initiated at much wider
scale, which should include development of effective anti-viral agents and vaccine strat‐
egies. Immunization is needed in JE prone areas. Over use of the vaccines should be avoided
otherwise the virus might develop resistance against drugs which are administered fre‐
quently. Quarantine checks should be done at international immigration and emigration
points, to keep a check on the spread of virus via foreign travelers. Vector control program
should be designed in a way that they can control the risk of vectors in an efficient way.
General awareness camps should be organized in rural areas to spread alertness in the local
population and confronting them with hygiene management and preventive measures. Sys‐
tematic and combinatorial approach with the joint efforts of scientists, molecular biologists,
doctors, drug developers, policy makers and local population is the need of hour. A high
sense of urgency is required to address this matter.
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